Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-007009
Filing Date
2025-05-08
Accepted
2025-05-08 17:15:56
Documents
88
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q iova-20250331x10q.htm   iXBRL 10-Q 2386493
2 EX-31.1 iova-20250331xex31d1.htm EX-31.1 12234
3 EX-31.2 iova-20250331xex31d2.htm EX-31.2 12121
4 EX-32.1 iova-20250331xex32d1.htm EX-32.1 6997
5 EX-32.2 iova-20250331xex32d2.htm EX-32.2 7062
  Complete submission text file 0001558370-25-007009.txt   10020723

Data Files

Seq Description Document Type Size
6 EX-101.SCH iova-20250331.xsd EX-101.SCH 67264
7 EX-101.CAL iova-20250331_cal.xml EX-101.CAL 63640
8 EX-101.DEF iova-20250331_def.xml EX-101.DEF 302210
9 EX-101.LAB iova-20250331_lab.xml EX-101.LAB 520647
10 EX-101.PRE iova-20250331_pre.xml EX-101.PRE 457434
91 EXTRACTED XBRL INSTANCE DOCUMENT iova-20250331x10q_htm.xml XML 1702599
Mailing Address 825 INDUSTRIAL ROAD 4TH FLOOR SAN CARLOS CA 94070
Business Address 825 INDUSTRIAL ROAD 4TH FLOOR SAN CARLOS CA 94070 6502607120
IOVANCE BIOTHERAPEUTICS, INC. (Filer) CIK: 0001425205 (see all company filings)

EIN.: 753254381 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36860 | Film No.: 25927404
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)